



# The Ethics of Research with Stored Samples and Data

**Sara Chandros Hull, Ph.D.**

Bioethics Core, NHGRI

*and*

Department of Bioethics, Clinical Center

National Institutes of Health

# Disclaimers/Disclosures

- No statement in this presentation should be construed as an official position of the National Human Genome Research Institute, National Institutes of Health, or Department of Health and Human Services.
- The speaker declares no financial conflicts of interest.

# Roadmap

- Setting the stage
- Two cases
- What is a human subject?
  - Large sample/data collections
  - U.S. regulatory framework
- Informed consent for collection, storage, and future use of samples/data
  - Broad
  - Study-specific



# Future of Genomic Research

“Complete characterization of the genetics of complex diseases will require the identification of the full spectrum of human genomic variation *in large, diverse sample sets.*”

Green E, Guyer M, and NHGRI (2011) “Charting a course for genomic medicine from base pairs to bedside.” *Nature*. 470: 204-13.


# The Basic Challenge

How to get informed consent for future research that is not fully anticipated at the time of sample collection?



# Related Challenges

- Was the consent process for existing collections of samples sufficient to permit new analyses, techniques, questions?
- When does a new use require specific consent?
  - Which, in some cases, might require re-contacting donors of samples for “re-consent”



# Where are samples collected and stored?

*n > 282 million in U.S., 20 mil new cases per year, NBAC (1999)*

- Clinical
  - Pathology departments
  - Cord blood banks
  - Blood banks
- Research
  - Individual laboratories
  - Repositories/biobanks
- Public Health/State
  - Newborn screening programs
  - Military DNA collections
  - Forensic collections

# What Are the Risks?

- Informational risk/disclosure
  - To participants
    - Anxiety/uncertainty
    - Familial
  - To third parties
    - Stigmatization
    - Discrimination
    - Group harms

# Case 1: BRCA, Tamoxifen, and Consent

- BCPT (n>13,000): found that tamoxifen significantly reduced incidence of invasive breast cancer in high-risk women
  - Conducted 1992-1998, before BRCA1/2 cloned
  - Study did not show *who* would benefit most
- Investigators wanted to go back to DNA samples to test for BRCA1/2 mutations

Fisher *et al.* 1998, *J Natl Cancer Inst*; MC King *et al.*, 2001, *JAMA*

# Case 1: BRCA, Tamoxifen, and Consent

- Women had not given explicit consent for BRCA1/2 genetic testing
  - General consent for future genetic research

# Case 1: BRCA, Tamoxifen, and Consent

- Women had not given explicit consent for BRCA1/2 genetic testing
  - General consent for future genetic research
- Subjects were informed about the new study
  - Given opportunity to “opt out” and withdraw DNA sample
- Samples were “anonymized”
  - No genetic results given

# Case 1: BRCA, Tamoxifen, and Consent

- Appropriately or overly cautious approach?
  - Prior consent sufficient for breast cancer genetics
  - Little evidence of harms
    - From discrimination
    - From receipt of BRCA results
  - Reduced scientific utility of samples/data
  - Non-disclosure of potentially beneficial information

# Case 1: BRCA, Tamoxifen, and Consent

- What if...
  - The researchers wanted to study genetics of cardiovascular disease using these samples?
  - The researchers wanted to sequence these samples
    - And deposit the data in a public repository?



# What is a human research subject?






# Current Definition of Human Subject

(f) A living individual from whom an investigator . . . conducting research obtains:

(1) data through intervention or interaction with the individual

45 CFR 46.102

# What is a Human Subject?





# Current Definition of Human Subject

(f) A living individual from whom an investigator . . . conducting research obtains:

- (1) data through intervention or interaction with the individual
- (2) identifiable private information

45 CFR 46.102

# Classification of Samples

**identifiable**

**cannot be identified/  
de-identified**



# OHRP Interpretation:

*not identifiable = not readily ascertainable*

- “OHRP does not consider research involving only coded private information or specimens to involve human subjects . . . if the following conditions are both met:
  - (1) the private information or specimens were not collected specifically for the proposed research . . . and
  - (2) the investigators cannot readily ascertain the identity of the individual(s)”

OHRP Guidance, 8/10/04

# A Moving Target

- NPRM (2015) proposal:
  - To expand the definition of human subjects to include research in which an investigator obtains, uses, studies, or analyzes a biospecimen
    - Regardless of the identifiability of the biospecimen
  - To create an exemption for secondary research using biospecimens or identifiable private information
    - With initial consent (broad or specific)

# What information is needed for valid informed consent?

**Consent for Specimen Collection**



# What information is needed for valid informed consent?



- *I consent to the donation of my tissues for research and education. If you wish to decline donation, indicate with your initials here\_\_\_\_\_.*

Grizzle et al (1999) *Arch Pathol Lab Med*

# What information is needed for valid informed consent?



- *I consent to the donation of my tissues for research and education. If you wish to decline donation, indicate with your initials here\_\_\_\_\_.*

- Specific disease*
- Particular gene*
- Explicit methodology*
- Individual investigator*
- Distinct time*

Grizzle et al (1999) *Arch Pathol Lab Med*

NBAC (1999)

# Variable consent practices

- “We observed considerable variability in consent form content regarding the conditions under which secondary research might be conducted.” (n=258)

IRB

ETHICS  
&  
HUMAN RESEARCH


MAY-JUNE 2004 • VOLUME 26, NUMBER 3

**Genetic Research Involving  
Human Biological Materials:**  
*A Need to Tailor Consent Forms*

BY SARA CHANDROS HULL, HOLLY GOODING, ALISON P. KLEIN, ESTHER  
WARSHAUER-BAKER, SUSAN METOSKY, AND BENJAMIN S. WILFOND

**Genetic Research Involving  
Human Biological Materials: A  
Need to Tailor Consent Forms**

# What information is needed for valid informed consent?



- *I consent to the donation of my tissues for research and education. If you wish to decline donation, indicate with your initials here\_\_\_\_\_.*

- Specific disease*
- Particular gene*
- Explicit methodology*
- Individual investigator*
- Distinct time*

Grizzle et al (1999) *Arch Pathol Lab Med*

NBAC (1999)

# Approaches to Consent for Future Research with Biospecimens

Less  
burden, less  
control

TYPE	DESCRIPTION
No consent	Do not obtain donor consent
Blanket	Consent to future research with no limitations
Broad*	Consent to future research with specified limitations
Checklist	Consent to specific types of future studies allowed
Study specific	Consent for each specific future study

More  
burden,  
more  
control

\*Framework proposed here couples initial broad consent with oversight and the possibility of ongoing communication



# Components of “Broad” Consent

1. Initial broad consent
2. Process of oversight and approval for future research activities
3. Wherever feasible, an ongoing process of providing information/communicating with donors

Christine Grady *et al.* (2015)  
*American Journal of Bioethics*

# Attitudinal Data

- The majority of individuals are willing to provide one-time broad consent and rely on independent ethics approval to determine the specific studies for which their samples are used
  - Regardless of disease, technology, etc.

# One-time general consent for research on biological samples

BMJ VOLUME 332 4 MARCH 2006

David Wendler

## Summary points

---

It is now recognised that people should give informed consent for the use of their biological samples in research

---

The types of consent needed and when consent should be obtained have not been defined

---

Studies have collected data on the views of more than 33 000 people on this issue

---

These data support one-time general consent

# Broad Consent in Policies (Min. Std)

- NIH Genomic Data Sharing Policy
  - “NIH expects investigators to obtain participants’ consent for their genomic and phenotypic data to be used for future research purposes and to be shared broadly.”
- NPRM (Common Rule)
  - Requires broad consent for all use of stored biospecimens in secondary research, including de-identified
  - Establishment DHHS broad consent templates

# What about the minority of individuals who are unwilling to give broad consent?

- Broad consent provides opportunity to say “no”
- However, concern that this approach excludes/alienates certain populations
  - If, for example, they object to specific downstream uses

# Genetic Research as a Double-Edged Sword

- Non-European populations are persistently underrepresented in genomic research/databases
  - “GWAS funded by the NIH and other sources are continuing to miss a vast portion of the world’s genetic variation”

Popejoy and Fullerton (2016) *Nature*

# Genetic Research as a Double-Edged Sword

- Some underrepresented populations are reluctant to participate in open-ended genomic research with broad sharing of samples and data
  - Genetic/genomic research poses risks to groups
  - Historical stigmatization, discrimination, failure to obtain/respect informed consent

# Case 2: Havasupai Tribe

## Indian Tribe Wins Fight to Limit Research of Its DNA



Jim Wilson/The New York Times

Edmond Tilousi, 56, who can climb the eight miles to the rim of the Grand Canyon in three hours. [More Photos »](#)

By AMY HARMON

Published: April 21, 2010

# Case 2: Havasupai Timeline

- **1990-1994** Havasupai DNA samples collected for genetic studies on T2D by ASU researchers
- **2003** Discovery that samples also used for research on schizophrenia, migration, inbreeding
- **2004** *Havasupai Tribe of the Havasupai Reservation v. Arizona Board of Regents and Therese Ann Markow*
- **2010** Settlement (\$770K, funds for clinic and school, return of DNA samples to Tribe)

# Case 2: What are the lessons?

- Two common explanations:
  - Individual researchers making bad choices
  - Communities exerting inappropriate control over otherwise good research
- “[A] profound disconnect exists between common academic research practices and legitimate community expectations, and justice requires that this gap be bridged.”

Goering, Holland, and Fryer-Edwards (2008) *HCR*

# Requirements for Ethical Research

1. *Collaborative partnership*
2. Social value
3. Scientific validity
4. Fair selection of study population
5. Favorable risk-benefit ratio
6. Independent review
7. Informed consent
8. *Respect for recruited participants and study communities*

Emanuel, Wendler, Killen, Grady (2004) *JID*

# Consonance with Community-Based Participatory Research

- Move from standard “principle” ethics to community dialogue and negotiations
- Room for innovative arrangements
- Assist in building cross-cultural equitable relationships between communities and researchers

Quigley (2006) *Health Education and Behavior*

# A Role for Empirical Data & Consultation

- To identify approaches that are consistent with the views and preferences of individuals and communities
- To examine clinical and social factors associated with particular opinions (e.g., cultural/population divides)
- To study the outcome of different consent approaches
  - e.g., rates of enrollment, cost and burden, facilitating more research

# Native Hawaiian Views

## Discussion groups (n=92) with Native Hawaiians

- “If I’m going to give my tissue to anyone for any cause, I want to know what the purpose of that is for. I don’t feel comfortable giving a generic sample and willy-nilly let people do what they want with that.”
- “[D]on’t just take my tissue and use it for diabetes; take my tissue and use it for diabetes to help the Native Hawaiians. That I can agree to...because we don’t have enough studies on us, the Native Hawaiians, so that we can get medicines that complement us.”

Tauali`I et al (2014) *Journal of Cancer Education*

# Alaska Area Specimen Bank


- Working Group
  - A resource of the Alaska Native people held in trust to be used to benefit the health and well-being of Alaska Native people
  - Individual specimens are property of the study participant who provided consent to have that specimen banked for future study; participant can request to have the specimen removed at any time.
- CDC + Alaska Area IRB approval

Parkinson et al (2013) *Int J Circumpolar Health*

# Alaska Area Specimen Bank

266,353 specimens

## Specimens by year



Parkinson et al (2013) *Int J Circumpolar Health*

# Thank you!